Abstract

Protocol Specific Research Support (PSRS) supports the conduct of innovative, high-priority phase I and phase l-ll investigator-initiated trials led by AECC investigators. In order to be eligible for PSRS, the study must be led by AECC investigator or resulted from previous clinical or preclinical studies performed at AECC (with AECOM faculty as co-investigator). A process has been established for designating PSRS, which includes a screen by the CPDMU for eligibility, evaluating the scientific merit of the study (as determined by the PRMC), and assigning priority relative to other AECC investigator-initiated trials. During the last funding period, trials supported by PSRS included protocols evaluating the clinical and immune effects of an HspE7 vaccine in patients with CINIII, the clinical and biologic effects of combining the farnesyltransferase inhibitor tipifarnib with standard chemotherapy in locally advanced breast cancer, and defining the recommended phase II dose, pharmacokinetics, and pharmacodynamics of the epothilone B analog ixabepilone. These studies have led to additional CTEP-sponsored and industry-sponsored phase II and phase III trials evaluating the effects of HsPE7 patients with CINIII, tipifarnib in locally advanced breast cancer, and ixabepilone in patients with advanced breast cancer.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013330-37
Application #
7886705
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
37
Fiscal Year
2009
Total Cost
$263,817
Indirect Cost

  Institution

Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461

  Publications

Sharma, Yogeshwar; Liu, Jinghua; Kristian, Kathleen E et al. (2018) In Atp7b-/- Mice Modeling Wilson's Disease Liver Repopulation with Bone Marrowderived Myofibroblasts or Inflammatory Cells and not Hepatocytes is Deleterious. Gene Expr :
Iqbal, Niloy Jafar; Lu, Zhonglei; Liu, Shun Mei et al. (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI Insight 3:
De Martino, Daniela; Yilmaz, Emrullah; Orlacchio, Arturo et al. (2018) PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett 439:56-65
Norwood Toro, Laura E; Wang, Yarong; Condeelis, John S et al. (2018) Myosin-IIA heavy chain phosphorylation on S1943 regulates tumor metastasis. Exp Cell Res 370:273-282
Agalliu, Ilir; Chen, Zigui; Wang, Tao et al. (2018) Oral Alpha, Beta, and Gamma HPV Types and Risk of Incident Esophageal Cancer. Cancer Epidemiol Biomarkers Prev 27:1168-1175
Bhargava, Ragini; Sandhu, Manbir; Muk, Sanychen et al. (2018) C-NHEJ without indels is robust and requires synergistic function of distinct XLF domains. Nat Commun 9:2484
Collu, Giovanna M; Jenny, Andreas; Gaengel, Konstantin et al. (2018) Prickle is phosphorylated by Nemo and targeted for degradation to maintain Prickle/Spiny-legs isoform balance during planar cell polarity establishment. PLoS Genet 14:e1007391
Doyle, Christopher R; Moon, Jee-Young; Daily, Johanna P et al. (2018) A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice. Infect Immun 86:
Anayannis, Nicole V; Schlecht, Nicolas F; Ben-Dayan, Miriam et al. (2018) Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. PLoS One 13:e0191581
Stepankova, Martina; Bartonkova, Iveta; Jiskrova, Eva et al. (2018) Methylindoles and Methoxyindoles are Agonists and Antagonists of Human Aryl Hydrocarbon Receptor. Mol Pharmacol 93:631-644

Showing the most recent 10 out of 1508 publications